Skip to main content
Gencurix Inc. logo

Gencurix Inc. — Investor Relations & Filings

Ticker · 229000 ISIN · KR7229000005 KO Manufacturing
Open in API
Filings indexed 405 across all filing types
Latest filing 2023-03-23 Investor Presentation
Country KR South Korea
Listing KO 229000

About Gencurix Inc.

https://www.gencurix.com/eng/

Gencurix Inc. is a molecular diagnostics company that develops and commercializes diagnostic solutions for precision medicine. The company's portfolio focuses primarily on oncology, offering prognostic, companion, and early detection tests. Key products include GenesWell BCT, a multigene prognostic test for early-stage breast cancer, and the GenesWell ddEGFR Mutation Test, a ddPCR-based companion diagnostic. Gencurix also utilizes its Droplex liquid biopsy platform for early cancer detection and develops diagnostic tests for infectious diseases. The company's core technologies include digital droplet PCR (ddPCR), real-time PCR, and liquid biopsy for analyzing circulating tumor cells (CTCs) and cell-free DNA (cfDNA).

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권) (2023.04)
Investor Presentation Classification · 95% confidence The document is a '증권신고서(지분증권) 정정신고' (Securities Registration Statement Amendment) filed by Gencurix. It details amendments to a previously filed securities registration statement, specifically updating financial data following the submission of the 2022 Annual Report. This type of regulatory filing, which provides updated financial risk factors and capital structure details for a securities offering, falls under the category of Regulatory Filings (RNS) as it is a formal amendment to a registration statement.
2023-03-23 Korean
[기재정정]투자설명서
Investor Presentation Classification · 95% confidence The document is a 'Correction Report' (정정신고) for a 'Securities Registration Statement' (투자설명서) filed by Gencurix. It details specific amendments to financial data, risk factors, and capital usage disclosures following the submission of the 2022 annual business report. In the context of financial filings, a registration statement or its amendment is classified as a 'Prospectus' or 'Offering Document', which falls under the 'POS' (Transaction in Own Shares/Capital Change) or 'SHA' category in many systems, but given the specific options provided and the nature of the document as a regulatory filing regarding capital structure and financial risk disclosure, it is best classified as a Regulatory Filing (RNS) or a Capital/Financing Update (CAP). Given the focus on capital structure, debt, and financial risk, 'CAP' is the most accurate fit.
2023-03-23 Korean
파생상품거래손실발생
Capital/Financing Update Classification · 100% confidence The document is a regulatory disclosure from a Korean company (Gencurix) regarding a 'Loss from Derivatives Transaction'. It details the nature of the loss (valuation loss on convertible bonds and preferred shares), the financial impact relative to equity, and the date of occurrence. Since this is a specific regulatory disclosure of a financial event that does not fit into standard periodic reports or other specific categories like M&A or dividends, it falls under the general regulatory filing category.
2023-03-23 Korean
기업설명회(IR)개최
Report Publication Announcement Classification · 100% confidence The document is a formal announcement regarding an upcoming 'Corporate IR Meeting' (기업설명회). It provides details such as the date, time, location (online), target audience, and the agenda for the meeting. Since this is a notification of an event rather than the presentation slides themselves or a comprehensive financial report, it falls under the category of general regulatory announcements or event notifications. Given the specific nature of the announcement regarding an IR event, 'RNS' (Regulatory Filings) is the most appropriate classification as it serves as a general regulatory notice for corporate activities.
2023-03-21 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting of Shareholders (주주총회소집결의) for the company Gencurix. It outlines the date, location, and agenda items for the upcoming Annual General Meeting (AGM), including the approval of financial statements, election of directors, and remuneration limits. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it falls under the Proxy Solicitation & Information Statement category.
2023-03-16 Korean
주주총회소집공고
AGM Information Classification · 100% confidence The document is a formal 'Notice of Annual General Meeting' (주주총회소집공고) for Gencurix. It contains the meeting agenda, details on voting procedures, and financial information (financial statements) provided as reference materials for shareholders to review prior to the meeting. According to the filing definitions, documents detailing materials shared for an AGM are classified as AGM-R.
2023-03-16 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.